Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma
Clinical trial NCT04849260 · UNKNOWN
Trial details
- NCT number
- NCT04849260
- Sponsor
- Lee's Pharmaceutical Limited
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-26
- Primary completion
- 2022-05-31
- Enrollment
- 54
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.